Incyte Corporation (NASDAQ: INCY) reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of $659.2...
Incyte Corporation (NASDAQ: INCY) reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of $659.2...
Incyte (INCY) shares were choppy during premarket trading after the company posted mixed first-quarter results owing tolower sales for its blockbuster blood disorder...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Neutral | Sell | Sell |
| Technical Indicators | Neutral | Strong Buy | Buy | Strong Sell | Strong Sell |
| Summary | Neutral | Strong Buy | Neutral | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,351.93 | 2,371.25 | 2,346.16 | +14.58 | +0.62% | 1.44M | NASDAQ | |||
| 319.08 | 322.94 | 318.75 | -0.94 | -0.29% | 15.92M | NASDAQ | |||
| 225.31 | 228.79 | 225.05 | -1.11 | -0.49% | 10.55M | NYSE | |||
| 0.878 | 0.00 | 0.00 | +0.0371 | +4.41% | 655.85K | NYSE | |||
| 151.21 | 157.05 | 148.78 | -2.43 | -1.58% | 7.13M | NASDAQ | |||
| 18.62 | 18.93 | 18.51 | +0.35 | +1.92% | 5.17M | NYSE | |||
| 620.46 | 631.80 | 608.33 | +11.38 | +1.87% | 363.53K | NASDAQ | |||
| 19.75 | 20.75 | 19.58 | -0.34 | -1.69% | 63.73M | NYSE | |||
| 191.55 | 198.49 | 189.51 | -0.78 | -0.41% | 7.43M | NASDAQ | |||
| 23.05 | 23.93 | 22.59 | +0.49 | +2.17% | 21.64M | NASDAQ | |||
| 116.83 | 119.42 | 116.05 | -0.17 | -0.15% | 9.61M | NYSE | |||
| 122.96 | 127.81 | 121.35 | +1.02 | +0.84% | 3.43M | NASDAQ | |||
| 67.90 | 68.48 | 66.20 | +2.84 | +4.37% | 4.81M | NYSE | |||
| 36.54 | 36.97 | 36.45 | +0.46 | +1.27% | 61.92K | OTC Markets | |||
| 119.87 | 120.77 | 119.25 | -0.16 | -0.13% | 892.32K | NASDAQ |
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.